Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Cardiology Reports
Published in: Current Cardiology Reports 7/2022

07-05-2022 | Systemic Lupus Erythematosus | Women and Cardiovascular Health (N Goldberg and S Lewis, Section Editors)

Assessment of Cardiac Risk in Women with Autoimmune Disease

Authors: Tyler Schmidt, Rekha Mankad

Published in: Current Cardiology Reports | Issue 7/2022

Login to get access

Abstract

Purpose of Review

The purpose of our review was to evaluate current standards in clinical practice in determining overall cardiac risk in female patients with chronic rheumatologic diseases. We hoped to not only summarize known cardiac manifestations of various chronic rheumatologic diseases but also determine the effectiveness of new risk scores in determining cardiac risk in this patient population.

Recent Findings

Chronic rheumatologic diseases have been associated with various cardiac manifestations for some time, with initial studies involving risk of coronary artery disease (CAD) in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). However, recent studies have shown numerous other cardiac manifestations associated with these and other chronic rheumatologic diseases. Risk scores have been used for several decades to help determine overall cardiac risk in the general population, but these risk scores have notoriously underestimated the risk of cardiac disease in woman and in patients with chronic rheumatologic diseases. These diseases, often with a female predominance, can impact long-term mortality and have devastating consequences if not monitored and treated appropriately. Thus, new risk scores have been developed over the last several years to help improve detection and awareness of cardiac disease in these patients.

Summary

Novel modified risk scores have found some success at improving the detection of cardiac disease in patients with chronic rheumatologic diseases. Further studies looking at these risk scores need to determine the accuracy of these scores and where they fall short. With the advent of advanced imaging technologies, future risk scores may involve certain imaging-based markers to help guide accurate risk determination.
Literature
1.
Jafri K, Ogdie A, Qasim A, Patterson SL, Gianfrancesco M, Izadi Z, et al. Discordance of the Framingham cardiovascular risk score and the 2013 American College of Cardiology/American Heart Association risk score in systemic lupus erythematosus and rheumatoid arthritis. Clin Rheumatol. 2018;37(2):467–74.PubMedCrossRef
2.
3.
4.
•• Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019;140(11):e596-e646. The 2019 ACC/AHA guidelines were some of the first major recommendations discussing the role of chronic rheumatologic diseases in the development of ASCVD.
5.
John H, Kitas G. Inflammatory arthritis as a novel risk factor for cardiovascular disease. Eur J Intern Med. 2012;23(7):575–9.PubMedCrossRef
6.
Mason JC, Libby P. Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions. Eur Heart J. 2014;36(8):482–9.PubMedPubMedCentralCrossRef
7.
Zacho J, Tybjærg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med. 2008;359(18):1897–908.PubMedCrossRef
8.
9.
Torres A, Askari AD, Malemud CJ. Cardiovascular disease complications in systemic lupus erythematosus. Biomark Med. 2009;3(3):239–52.PubMedCrossRef
10.
Rajavashisth TB, Liao JK, Galis ZS, Tripathi S, Laufs U, Tripathi J, et al. Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1-matrix metalloproteinase. J Biol Chem. 1999;274(17):11924–9.PubMedCrossRef
11.
12.
Souverein PC, Berard A, Van Staa TP, Cooper C, Egberts ACG, Leufkens HGM, et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case–control study. Heart. 2004;90(8):859–65.PubMedPubMedCentralCrossRef
13.
• Natsheh A, Shimony D, Bogot N, Nesher G, Breuer GS. Complete heart block in lupus. Lupus 2019;28(13):1589-1593. This review discussed numerous documented cases of complete heart block in the setting of systemic lupus erythematosus, highlighting this uncommon but serious consequence of the disease.
14.
Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Jacobsen SJ, Roger VL, et al. Raised erythrocyte sedimentation rate signals heart failure in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66(1):76–80.PubMedCrossRef
15.
Gabriel SE. The epidemiology of rheumatoid arthritis. Rheumatic Disease Clinics of North America. 2001;27(2):269–81.PubMedCrossRef
16.
Lindhardsen J, Ahlehoff O, Gislason GH, Madsen OR, Olesen JB, Torp-Pedersen C, et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis. 2011;70(6):929–34.PubMedCrossRef
17.
Gabriel SE, Crowson CS, Kremers HM, Doran MF, Turesson C, O’Fallon WM, et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum. 2003;48(1):54–8.PubMedCrossRef
18.
Myasoedova E, Chandran A, Ilhan B, Major BT, Michet CJ, Matteson EL, et al. The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease. Ann Rheum Dis. 2016;75(3):560–5.PubMedCrossRef
19.
Wahlin B, Meedt T, Jonsson F, Henein MY, Wållberg-Jonsson S. Coronary artery calcification is related to inflammation in rheumatoid arthritis: a long-term follow-up study. Biomed Res Int. 2016;2016:1261582.PubMedPubMedCentralCrossRef
20.
del Rincón ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2001;44(12):2737–45.PubMedCrossRef
21.
Lai C-H, Lai W-W, Chiou M-J, Lin W-C, Yang Y-J, Li C-Y, et al. Outcomes of percutaneous coronary intervention in patients with rheumatoid arthritis and systemic lupus erythematosus: an 11-year nationwide cohort study. Ann Rheum Dis. 2016;75(7):1350–6.PubMedCrossRef
22.
Kitas GD, Gabriel SE. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis. 2011;70(1):8–14.PubMedCrossRef
23.
Douglas KMJ, Pace AV, Treharne GJ, Saratzis A, Nightingale P, Erb N, et al. Excess recurrent cardiac events in rheumatoid arthritis patients with acute coronary syndrome. Ann Rheum Dis. 2006;65(3):348–53.PubMedCrossRef
24.
Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 2005;52(2):402–11.PubMedCrossRef
25.
Crowson CS, Therneau TM, Davis JM 3rd, Roger VL, Matteson EL, Gabriel SE. Brief report: accelerated aging influences cardiovascular disease risk in rheumatoid arthritis. Arthritis Rheum. 2013;65(10):2562–6.PubMedPubMedCentral
26.
Kremers HM, Crowson CS, Therneau TM, Roger VL, Gabriel SE. High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: a population-based cohort study. Arthritis Rheum. 2008;58(8):2268–74.PubMedCrossRef
27.
Izmirly PM, Parton H, Wang L, McCune WJ, Lim SS, Drenkard C, et al. Prevalence of systemic lupus erythematosus in the United States: estimates from a meta-analysis of the Centers for Disease Control and Prevention National Lupus Registries. Arthritis Rheumatol. 2021;73(6):991–6.PubMedPubMedCentralCrossRef
28.
Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum. 1999;42(2):338–46.PubMedCrossRef
29.
Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. 1997;145(5):408–15.PubMedCrossRef
30.
Artenjak A, Lakota K, Frank M, Čučnik S, Rozman B, Božič B, et al. Antiphospholipid antibodies as non-traditional risk factors in atherosclerosis based cardiovascular diseases without overt autoimmunity. A critical updated review Autoimmunity Reviews. 2012;11(12):873–82.PubMedCrossRef
31.
Salmon JE, Roman MJ. Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am J Med. 2008;121(10, Supplement 1):S3-S8.
32.
Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003;349(25):2407–15.PubMedCrossRef
33.
Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003;349(25):2399–406.PubMedCrossRef
34.
Miner JJ, Kim AH. Cardiac manifestations of systemic lupus erythematosus. Rheum Dis Clin North Am. 2014;40(1):51–60.PubMedCrossRef
35.
Ingegnoli F, Ughi N, Mihai C. Update on the epidemiology, risk factors, and disease outcomes of systemic sclerosis. Best Pract Res Clin Rheumatol. 2018;32(2):223–40.PubMedCrossRef
36.
Rubio-Rivas M, Royo C, Simeón CP, Corbella X, Fonollosa V. Mortality and survival in systemic sclerosis: systematic review and meta-analysis. Semin Arthritis Rheum. 2014;44(2):208–19.PubMedCrossRef
37.
• Pokeerbux MR, Giovannelli J, Dauchet L, Mouthon L, Agard C, Lega JC et al 2019 Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature. Arthritis Res Ther. 2019;21(1):86. This paper revealed the extent and various methods of cardiac invovlement of systemic sclerosis.
38.
•• Nie LY, Wang XD, Zhang T, Xue J. Cardiac complications in systemic sclerosis: early diagnosis and treatment. Chin Med J (Engl). 2019;132(23):2865-2871. This paper revealed the common causes of cardiovascular-related mortality in patients with systemic sclerosis.
39.
Cannarile F, Valentini V, Mirabelli G, Alunno A, Terenzi R, Luccioli F, et al. Cardiovascular disease in systemic sclerosis. Ann Transl Med. 2015;3(1):8.PubMedPubMedCentral
40.
Chu SY, Chen YJ, Liu CJ, Tseng WC, Lin MW, Hwang CY, et al. Increased risk of acute myocardial infarction in systemic sclerosis: a nationwide population-based study. Am J Med. 2013;126(11):982–8.PubMedCrossRef
41.
•• Duarte‐García A, Pham MM, Crowson CS, Amin S, Moder KG, Pruthi RK et al. The epidemiology of antiphospholipid syndrome: a population-based study. Arthritis Rheumatol 2019;71(9):1545-1552. This study revealed the prevalence and cardiac risk factors of antiphsopholipid antibody syndrome underscoring the importance of screening for these diagnoses.
42.
Chighizola CB, Andreoli L, de Jesus GR, Banzato A, Pons-Estel GJ, Erkan D. The association between antiphospholipid antibodies and pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Lupus. 2015;24(9):980–4.PubMedCrossRef
43.
Bartoloni E, Baldini C, Schillaci G, Quartuccio L, Priori R, Carubbi F, et al. Cardiovascular disease risk burden in primary Sjögren’s syndrome: results of a population-based multicentre cohort study. J Intern Med. 2015;278(2):185–92.PubMedCrossRef
44.
Gyöngyösi M, Pokorny G, Jambrik Z, Kovács L, Kovács A, Makula E, et al. Cardiac manifestations in primary Sjögren’s syndrome. Ann Rheum Dis. 1996;55(7):450–4.PubMedPubMedCentralCrossRef
45.
Sung MJ, Park SH, Kim SK, Lee YS, Park CY, Choe JY. Complete atrioventricular block in adult Sjögren’s syndrome with anti-Ro autoantibody. Korean J Intern Med. 2011;26(2):213–5.PubMedPubMedCentralCrossRef
46.
Jamnitski A, Symmons D, Peters MJ, Sattar N, McInnes I, Nurmohamed MT. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis. 2013;72(2):211–6.PubMedCrossRef
47.
Liew JW, Ramiro S, Gensler LS. Cardiovascular morbidity and mortality in ankylosing spondylitis and psoriatic arthritis. Best Pract Res Clin Rheumatol. 2018;32(3):369–89.PubMedCrossRef
48.
Lindhardsen J, Ahlehoff O, Gislason GH, Madsen OR, Olesen JB, Svendsen JH, et al. Risk of atrial fibrillation and stroke in rheumatoid arthritis: Danish nationwide cohort study. BMJ. 2012;344: e1257.PubMedPubMedCentralCrossRef
49.
Eisen A, Arnson Y, Dovrish Z, Hadary R, Amital H. Arrhythmias and conduction defects in rheumatological diseases–a comprehensive review. Semin Arthritis Rheum. 2009;39(3):145–56.PubMedCrossRef
50.
Teixeira RA, Borba EF, Bonfá E, Martinelli FM. Arrhythmias in systemic lupus erythematosus. Rev Bras Reumatol. 2010;50(1):81–9.PubMedCrossRef
51.
Bourré-Tessier J, Clarke AE, Huynh T, Bernatsky S, Joseph L, Belisle P, et al. Prolonged corrected QT interval in anti-Ro/SSA-positive adults with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2011;63(7):1031–7.CrossRef
52.
Ashrafi R, Garg P, McKay E, Gosney J, Chuah S, Davis G. Aggressive cardiac involvement in systemic lupus erythematosus: a case report and a comprehensive literature review. Cardiol Res Pract. 2011;2011: 578390.PubMedPubMedCentralCrossRef
53.
Didier K, Bolko L, Giusti D, Toquet S, Robbins A, Antonicelli F, et al. Autoantibodies associated with connective tissue diseases: what meaning for clinicians? Front Immunol. 2018;9:541.PubMedPubMedCentralCrossRef
54.
Seferović PM, Ristić AD, Maksimović R, Simeunović DS, Ristić GG, Radovanović G, et al. Cardiac arrhythmias and conduction disturbances in autoimmune rheumatic diseases. Rheumatology (Oxford). 2006;45 Suppl 4:iv39–42.
55.
Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56–528.PubMedCrossRef
56.
Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet. 2012;380(9859):2163–96.CrossRef
57.
Nicola PJ, Maradit-Kremers H, Roger VL, Jacobsen SJ, Crowson CS, Ballman KV, et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum. 2005;52(2):412–20.PubMedCrossRef
58.
•• Ahlers MJ, Lowery BD, Farber‐Eger E, Wang TJ, Bradham W, Ormseth MJ, et al. Heart failure risk associated with rheumatoid arthritis-related chronic inflammation. J Am Heart Assoc 2020;9(10):e014661. This paper discussed the incidence and pathophysiology of congestive heart failure in rheumatoid arthritis. For decades, cardiac involvement in rheumatoid arthritis was focused on coronary artery disease. However, this paper highlights the prevalence of other forms of cardiac involvement that occur in the setting of rheumatoid arthritis.
59.
Fitzpatrick JK, Meyer CS, Schiller NB, Whooley MA, Mishra RK. Ventricular-vascular coupling at rest and after exercise is associated with heart failure hospitalizations in patients with coronary artery disease. J Am Soc Echocardiogr. 2018;31(11):1212-20.e3.PubMedCrossRef
60.
Jiang H, Zhang L, Yu Y, Liu M, Jin X, Zhang P, et al. A pilot study of angiogenin in heart failure with preserved ejection fraction: a novel potential biomarker for diagnosis and prognosis? J Cell Mol Med. 2014;18(11):2189–97.PubMedPubMedCentralCrossRef
61.
Bartels CM, Buhr KA, Goldberg JW, Bell CL, Visekruna M, Nekkanti S, et al. Mortality and cardiovascular burden of systemic lupus erythematosus in a US population-based cohort. J Rheumatol. 2014;41(4):680–7.PubMedPubMedCentralCrossRef
62.
Puntmann VO, D'Cruz D, Smith Z, Pastor A, Choong P, Voigt T, et al. Native myocardial T1 mapping by cardiovascular magnetic resonance imaging in subclinical cardiomyopathy in patients with systemic lupus erythematosus. Circulation: Cardiovascular Imaging. 2013;6(2):295–301.
63.
Tselios K, Urowitz MB. Cardiovascular and pulmonary manifestations of systemic lupus erythematosus. Curr Rheumatol Rev. 2017;13(3):206–18.PubMedCrossRef
64.
Chen J, Tang Y, Zhu M, Xu A. Heart involvement in systemic lupus erythematosus: a systemic review and meta-analysis. Clin Rheumatol. 2016;35(10):2437–48.PubMedCrossRef
65.
Wislowska M, Dereń D, Kochmański M, Sypuła S, Rozbicka J. Systolic and diastolic heart function in SLE patients. Rheumatol Int. 2009;29(12):1469–76.PubMedCrossRef
66.
Adler Y, Charron P, Imazio M, Badano L, Barón-Esquivias G, Bogaert J, et al. 2015 ESC guidelines for the diagnosis and management of pericardial diseases: the task force for the diagnosis and management of pericardial diseases of the European Society of Cardiology (ESC)endorsed by: the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015;36(42):2921–64.PubMedCrossRef
67.
Roman MJ, Salmon JE. Cardiovascular manifestations of rheumatologic diseases. Circulation. 2007;116(20):2346–55.PubMedCrossRef
68.
Rosenbaum E, Krebs E, Cohen M, Tiliakos A, Derk CT. The spectrum of clinical manifestations, outcome and treatment of pericardial tamponade in patients with systemic lupus erythematosus: a retrospective study and literature review. Lupus. 2009;18(7):608–12.PubMedCrossRef
69.
Sugiura T, Kumon Y, Kataoka H, Matsumura Y, Takeuchi H, Doi YL. Asymptomatic pericardial effusion in patients with systemic lupus erythematosus. Lupus. 2009;18(2):128–32.
70.
Vivero F, Gonzalez-Echavarri C, Ruiz-Estevez B, Maderuelo I, Ruiz-Irastorza G. Prevalence and predictors of valvular heart disease in patients with systemic lupus erythematosus. Autoimmun Rev. 2016;15(12):1134–40.PubMedCrossRef
71.
Galve E, Candell-Riera J, Pigrau C, Permanyer-Miralda G, Garcia-Del-Castillo H, Soler-Soler J. Prevalence, morphologic types, and evolution of cardiac valvular disease in systemic lupus erythematosus. N Engl J Med. 1988;319(13):817–23.PubMedCrossRef
72.
Watad A, Tiosano S, Grysman N, Comaneshter D, Cohen AD, Shoenfeld Y, et al. The association between systemic lupus erythematosus and valvular heart disease: an extensive data analysis. Eur J Clin Invest. 2017;47(5):366–71.PubMedCrossRef
73.
Beckhauser AP, Vallin L, Burkievcz CJ, Perreto S, Silva MB, Skare TL. Valvular involvement in patients with rheumatoid arthritis. Acta Reumatol Port. 2009;34(1):52–6.PubMed
74.
Bois JP, Crowson CS, Khullar T, Achenbach SJ, Krause ML, Mankad R. Progression rate of severity of aortic stenosis in patients with rheumatoid arthritis. Echocardiography. 2017;34(10):1410–6.PubMedPubMedCentralCrossRef
75.
•• Drosos GC, Konstantonis G, Sfikakis PP, Tektonidou MG. Underperformance of clinical risk scores in identifying vascular ultrasound-based high cardiovascular risk in systemic lupus erythematosus. Eur J Prev Cardiol. 2020:2047487320906650. This paper reviews clinical risk scores and their unreliability at detecting atherosclerotic cardiovascular disease in patients with systemic lupus erythematosus patients.
76.
Kawai V, Solus J, Oeser A, Rho Y, Raggi P, Bian A, et al. Novel cardiovascular risk prediction models in patients with systemic lupus erythematosus. Lupus. 2011;20(14):1526–34.PubMedPubMedCentralCrossRef
77.
Crowson CS, Matteson EL, Roger VL, Therneau TM, Gabriel SE. Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis. Am J Cardiol. 2012;110(3):420–4.PubMedPubMedCentralCrossRef
78.
Arts EE, Popa C, Den Broeder AA, Semb AG, Toms T, Kitas GD, et al. Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis. Ann Rheum Dis. 2015;74(4):668–74.PubMedCrossRef
79.
Myasoedova E, Crowson CS, Kremers HM, Roger VL, Fitz-Gibbon PD, Therneau TM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis. 2011;70(3):482–7.PubMedCrossRef
80.
Kremers HM, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum. 2004;50(11):3450–7.PubMedCrossRef
81.
Peters MJL, Symmons DPM, McCarey D, Dijkmans BAC, Nicola P, Kvien TK, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69(2):325–31.PubMedCrossRef
82.
Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ. 2008;336(7659):1475–82.PubMedPubMedCentralCrossRef
83.
Crowson CS, Gabriel SE, Semb AG, van Riel P, Karpouzas G, Dessein PH, et al. Rheumatoid arthritis-specific cardiovascular risk scores are not superior to general risk scores: a validation analysis of patients from seven countries. Rheumatology (Oxford). 2017;56(7):1102–10.CrossRef
84.
Shah T, Casas JP, Cooper JA, Tzoulaki I, Sofat R, McCormack V, et al. Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int J Epidemiol. 2009;38(1):217–31.PubMedCrossRef
85.
Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017;357: j2099.PubMedPubMedCentralCrossRef
86.
van Sijl AM, Peters MJ, Knol DK, de Vet HC, Gonzalez-Gay MA, Smulders YM, et al. Carotid intima media thickness in rheumatoid arthritis as compared to control subjects: a meta-analysis. Semin Arthritis Rheum. 2011;40(5):389–97.PubMedCrossRef
87.
Urowitz MB, Ibañez D, Su J, Gladman DD. Modified Framingham Risk Factor Score for systemic lupus erythematosus. J Rheumatol. 2016;43(5):875–9.PubMedCrossRef
88.
•• Petri MA, Barr E, Magder LS. Development of a systemic lupus erythematosus cardiovascular risk equation. Lupus Sci Med. 2019;6(1):e000346. This paper discusses the use of a novel risk score that more accurately predicted risk of cardiac disease in patients with systemic lupus erythematosus.
89.
Cypiene A, Kovaite M, Venalis A, Dadoniene J, Rugiene R, Petrulioniene Z, et al. Arterial wall dysfunction in systemic lupus erythematosus. Lupus. 2009;18(6):522–9.PubMedCrossRef
90.
Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(3):480–9.PubMedCrossRef
91.
Goodson NJ, Brookhart AM, Symmons DP, Silman AJ, Solomon DH. Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. Ann Rheum Dis. 2009;68(3):367–72.PubMedCrossRef
92.
Davis JM 3rd, Maradit Kremers H, Crowson CS, Nicola PJ, Ballman KV, Therneau TM, et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 2007;56(3):820–30.PubMedCrossRef
93.
Wilson JC, Sarsour K, Gale S, Pethö-Schramm A, Jick SS, Meier CR. Incidence and risk of glucocorticoid-associated adverse effects in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2019;71(4):498–511.CrossRef
94.
Lee JL, Sinnathurai P, Buchbinder R, Hill C, Lassere M, March L. Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study. Arthritis Res Ther. 2018;20(1):171.PubMedPubMedCentralCrossRef
95.
Rempenault C, Combe B, Barnetche T, Gaujoux-Viala C, Lukas C, Morel J, et al. Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2018;77(1):98–103.PubMedCrossRef
96.
Ljung L, Rantapää-Dahlqvist S, Jacobsson LT, Askling J. Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis. Ann Rheum Dis. 2016;75(12):2087–94.PubMedCrossRef
97.
Kume K, Amano K, Yamada S, Hatta K, Ohta H, Kuwaba N. Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial. J Rheumatol. 2011;38(10):2169–71.PubMedCrossRef
98.
Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371(9617):987–97.PubMedCrossRef
99.
•• Singh S, Fumery M, Singh AG, Singh N, Prokop LJ, Dulai PS, et al. Comparative risk of cardiovascular events with biologic and synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2020;72(4):561-576. This paper reviews advanced treatment modalities for rheumatoid arthritis and their associated risk/benefit in the development of cardiac disease in this patient population.
100.
Muangchan C, Harding S, Khimdas S, Bonner A, Baron M, Pope J. Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group. Arthritis Care Res (Hoboken). 2012;64(9):1405–14.CrossRef
101.
Panoulas VF, Douglas KM, Milionis HJ, Stavropoulos-Kalinglou A, Nightingale P, Kita MD, et al. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology (Oxford). 2007;46(9):1477–82.CrossRef
Metadata
Title
Assessment of Cardiac Risk in Women with Autoimmune Disease
Authors
Tyler Schmidt
Rekha Mankad
Publication date
07-05-2022
Publisher
Springer US
Published in
Current Cardiology Reports / Issue 7/2022
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-022-01698-1

Other articles of this Issue 7/2022

Current Cardiology Reports 7/2022 Go to the issue

Public Health Policy (SS Virani and D Mahtta, Section Editors)

COVID’s Impact on Non-communicable Diseases: What We Do Not Know May Hurt Us

New Therapies for Cardiovascular Disease (AA Bavry and M Massoomi, Section Editors)

Pulsed Field Ablation: a Novel Therapeutic Tool for Catheter-Based Treatment of Atrial Fibrillation

Diabetes and Cardiovascular Disease (D Bruemmer, Section Editor)

Exercise and Self-Management in Adults with Type 1 Diabetes

Invasive Electrophysiology and Pacing (EK Heist, Section Editor)

Concomitant Surgical Left Atrial Appendage Occlusion: a Review

Myocardial Disease (A Abbate and M Merlo, Section Editor)

Imaging-Guided Treatment for Cardiac Amyloidosis

Peripheral Vascular Disease (WS Jones, Section Editor)

Atherectomy vs Other Modalities for Treatment During Peripheral Vascular Intervention

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits